Originally, Rhythm licensed the melanocortin 4 receptor (MC4R) candidate, known at the time as LB54640, from LG for $80 ...
AbbVie has scrapped a phase 2 solid tumor drug after deciding that the monoclonal antibody was unlikely to best the current ...
The FDA has accepted uniQure’s applicatoin for its Huntington’s disease gene therapy under priority review, alongside a tentative plan to convene an advisory committee meeting. | The FDA has accepted ...
Tiziana Life Sciences’ intranasal drug has hit the dual endpoints of a phase 2a study in patients with a form of multiple sclerosis (MS), although the win was slightly marred by the higher dose ...
The FDA has put a partial hold on Biosciences’ seizure study application over preclinical toxicity data and concerns about ...
Eli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results